- Global Benefits Vision - https://www.global-benefits-vision.com/ -

AM Best clarifies how it rates captive cell structures

In November 2026, AM Best published a special report answering questions about the rating of cell captive companies and other alternative risk transfer entities. The FAQ was released on 12 November and explains how AM Best applies criteria it last revised in August 2025. The November publication is guidance on applying that methodology. It does not announce a new rating for any particular sponsor or cell.

An employer evaluating a captive cell to finance employee benefits can use the guidance to ask a practical question: which legal entity is being rated, and how does that assessment relate to the entity taking its risk? A fronting insurer may issue the local policy and cede an agreed share of risk to a captive structure. The fronting insurer, the cell company and an incorporated cell perform different roles. A rating associated with one does not establish the financial strength of the others.

Understand how the cell is organised

AM Best’s 2025 criteria set out a route to issuer credit and financial strength ratings for individual incorporated cells. They do not imply that every incorporated cell qualifies for a rating or already has one. The November FAQ highlights segregated funds, the effect of stress and the ability to obtain extra funding when analysing incorporated structures. Ask the sponsor to explain which assets and funding commitments actually back the cells involved and how they work in the relevant domicile.

For unincorporated cell companies, AM Best describes a weakest link approach. Its analysis considers whether each cell is adequately capitalised and how financial strain in a cell might affect its own capital or the wider company. That approach makes the quality of information about the wider structure relevant to a prospective participant. The precise exposure depends on the applicable law and contracts; do not infer legal recourse from the rating methodology alone.

Match the rated entity to the risk

Start by tracing the contracts. Identify the insurer that owes policy benefits, the entity assuming reinsurance risk, the holder of the collateral and the party expected to fund a shortfall. Compare those names with the identity of the entity in the current rating disclosure. A portfolio can look well protected at a group level while an individual programme relies on narrower support under a reinsurance agreement.

AM Best says it expects the cell sponsor to provide material such as audited financial statements, important agreements, licences, business plans and insurance and reinsurance policies. It may also look at local regulation and seek legal or actuarial input. An employer need not reproduce the agency’s work. It can, however, ask for evidence that its chosen arrangement has enforceable collateral and funding provisions and can continue to pay claims under the stresses that matter to its benefits programme.

A multinational programme should stress scenarios that reflect the cover it cedes. For group life, consider several large claims arriving together. For medical reinsurance, consider several adverse renewals or delayed claim reporting. Ask who would post additional collateral, how quickly funds would be available and whether a dispute or a change in fronting arrangements would interrupt that process. Consider the treatment of outstanding claims if the employer leaves the cell.

Bring the questions to the board

Independent non-executive directors can ask management to reconcile the rated legal entity with the programme’s contract and capital structure before approval. They can also challenge assumptions about access to funds under stress and ask management to bring evidence of collateral, claims continuity and any sponsor conflicts back to the board at renewal.

Use the FAQ as the basis for a short diligence note before placement or renewal. It should name each rated entity, map the contracts and cash flows, and show who would fund a shortfall on the timetable claims require. Record separately any assumptions that still need confirmation from the fronting insurer, cell sponsor or local advisers. Those questions give boards a way to use an external rating alongside the evidence specific to their own programme.

Sources

AM Best: special report announcement

AM Best – Rating Captives and Other Alternative Risk Transfer Entities criteria, August 2025